Merck Shifts Focus from GARDASIL Decline to New Pipeline Opportunities
Merck (MRK) is moving away from its previous focus on declining sales of the HPV vaccine, GARDASIL. A year ago, management was addressing a significant drop in China-related sales for the product; however, by mid-2026, revenue had stabilized at $1.2 billion and even showed slight growth when excluding currency effects. The company is now emphasizing its broader pipeline of new products as it prepares for the eventual loss of exclusivity on KEYTRUDA, a top-selling drug that generated $8.4 billion in Q2 2026 alone. Merck highlighted recent FDA approvals and positive clinical trial results for LIPFENDRA (an oral PCSK9 inhibitor) and sac-TMT as key milestones. Despite near-term challenges such as the Terns Pharmaceuticals acquisition charge, which led to a loss in Q2 2026, management raised its full-year revenue guidance. The company is betting on long-term growth from these new products rather than relying solely on GARDASIL or KEYTRUDA.
Tickers: $BMY $JNJ $LLY $MRK $PFE
Topics: KEYTRUDA exclusivity management strategy pharmaceutical vaccine sales